A RIPK2 activity signature in prostate cancer: Modulation by RIPK2 inhibition and clinical association
Ahmed M. Elgehama, Qian Yang, Jaceline Gislaine Pires Sanches, Zaoke He, Lauryn Ruegg, Sungyong You, Wei Yang · 2026
Read A RIPK2 activity signature in prostate cancer: Modulation by RIPK2 inhibition and clinical association by Ahmed M. Elgehama, Qian Yang, Jaceline Gislaine Pires Sanches, Zaoke He, Lauryn Ruegg, Sungyong You, Wei Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13197725.txt.
Description
Ahmed Elgehama and six co-authors built in 2026 a gene signature that reports how active a cancer drug target is inside prostate tumors. The target, a kinase called RIPK2, draws drug developers, but trials need a way to tell whose tumors truly run on it. The team deleted the gene in three prostate cancer cell lines and sequenced what changed.
Thirteen candidate genes shrank to a validated eight-gene score. Two different blocking drugs lowered the score in step with dose and time across five cell lines. A working activity meter could match patients to the drug and prove it bites.
Catalog record
| CREATOR | Ahmed M. Elgehama, Qian Yang, Jaceline Gislaine Pires Sanches, Zaoke He, Lauryn Ruegg, Sungyong You, Wei Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |